**Slashes CAR-T Exhaustion While Enabling Rapid Manufacturing for Solid Tumor Therapies**

Background

Adoptive cell therapies, such as chimeric antigen receptor (CAR) T cell and transgenic T cell therapies, have emerged as transformative modalities for treating autoimmune diseases and various cancers, including solid tumors like hepatocellular carcinoma. The clinical success of these immunotherapies heavily relies on the ability of the engineered T cells to survive and maintain their therapeutic potency after patient infusion. Consequently, there is a critical need for strategies that promote a long-lived effector state in T cells, ensuring they can persist and sustain robust anti-tumor activity in the hostile tumor microenvironment.

However, achieving sustained T cell persistence remains a major hurdle, as modified cells frequently undergo terminal differentiation and exhaustion, limiting their long-term efficacy. While genetic modifications have been explored to potentiate these cellular products, current approaches present significant manufacturing challenges. Existing methods typically require continuous gene induction throughout the entire ex vivo manufacturing process to achieve the desired phenotype. This requirement complicates production, increases costs, and makes these strategies largely incompatible with the short, streamlined manufacturing pipelines increasingly favored by pharmaceutical companies for rapid and scalable patient delivery.

Technology

This technology utilizes specialized gene expression cassettes to induce the expression of the transcription factor ZNF683 (also known as HOBIT) in chimeric antigen receptor (CAR) and transgenic T cells. By upregulating ZNF683, the solution drives T cells into a long-lived effector state, ensuring they persist both in vitro and in vivo while maintaining potent, sustained activity against tumor cells. The primary application is to enhance the efficacy of engineered T cell therapies for solid tumors, such as hepatocellular carcinoma, as well as autoimmune diseases. Furthermore, these expression cassettes can potentially be delivered via lipid nanoparticles, RNA, or viral vectors to boost endogenous T cell responses, and they can incorporate an inducible caspase 9 safety switch to mitigate any theoretical toxicity risks.

This approach is uniquely differentiated by both its biological mechanism and its manufacturing flexibility. Prevailing scientific views previously considered ZNF683 strictly as a phenotypic marker or assumed its expression was detrimental to T cell longevity, similar to the related BLIMP1 gene. However, this solution leverages the novel discovery that ZNF683 actively promotes a persistent, anti-tumor effector state rather than terminal differentiation. Additionally, existing methods for potentiating CAR T cells require continuous gene induction throughout the ex vivo manufacturing process, complicating production. In contrast, ZNF683 induction can be initiated either during manufacturing or directly during patient treatment, making it uniquely compatible with the short, efficient manufacturing pipelines favored by pharmaceutical companies.

Benefits

• Enhances the in vivo and in vitro persistence of CAR T cells
• Sustains long-term anti-tumor activity in the presence of tumor cells
• Promotes a long-lived effector state in human T cells without causing terminal differentiation
• Offers manufacturing flexibility by allowing gene induction either during production or during patient treatment
• Integrates seamlessly with both short and long commercial manufacturing protocols, reducing production complexity
• Provides broad therapeutic applicability for solid tumors, such as hepatocellular carcinoma, and autoimmune diseases
• Enables potential in vivo enhancement of endogenous T cell responses via lipid nanoparticles, RNA, or viral vectors

Applications

• Solid tumor CAR-T therapy
• Hepatocellular carcinoma immunotherapy
• Autoimmune disease T-cell therapy
• Transgenic T-cell therapy enhancement
• In vivo T-cell reprogramming